Market Overview

Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting


Company will give an oral presentation of 6-month efficacy data on
CNTX-4975 for the treatment of moderate to severe osteoarthritis knee

Therapeutics Corporation
, a company focused on developing
non-opioid, non-steroidal therapeutics for the treatment of chronic
pain, today announced it will present Phase 2b data of CNTX-4975 for the
treatment of moderate to severe osteoarthritis knee pain at 4:00 p.m.
CST on Tuesday, March 6 at the American Academy of Orthopaedic Surgeons
(AAOS) Annual Meeting taking place from March 6-10, 2018 at the Ernest
N. Morial Convention Center in New Orleans, LA.

More information can be found at
Details of the oral presentation are listed below.

Title: Intra-articular CNTX-4975 for Osteoarthritis Knee Pain:
Analyses From a 24-Week Randomized Phase 2b Study
Paper Number: 868
Adult Reconstruction Knee IX (868-882)
Tuesday, March 6 at 4:00 p.m. CST
Location: Theater
A, Ernest N. Morial Convention Center

About Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting
approximately 14 million people in the United States.1 OA
occurs when the protective cartilage on the ends of the bones wears down
over time, and the bone around the joints harden and form edges. These
changes cause pain, swelling and problems moving the joint. OA also
causes an inflammatory process to occur in the affected joint, further
damaging the cartilage. Although OA can damage the majority of joints in
the body, it most commonly affects joints in the knees, hips, hands and
spine. OA can cause pain severe enough that patients experience
difficulty walking, climbing stairs or even rising from a chair. Despite
currently available therapies, many patients opt for total joint
replacement to manage the painful condition.

About CNTX-4975

CNTX-4975 is based on Centrexion's proprietary STRATI™ technology
(Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent,
ultra-pure, synthetic form of trans-capsaicin. CNTX-4975 is designed to
be injected directly into the site of pain to provide rapid onset, large
reduction and long duration of relief from moderate to severe joint pain
without affecting touch sensibility or position sense. CNTX-4975 works
by targeting the capsaicin receptor (TRPV1) to selectively and rapidly
inactivate the local pain fibers transmitting signals to the brain. With
a short half-life, CNTX-4975 is cleared from the body within 24 hours.
This approach is designed to provide pain relief that can last for
months until the ends of the local pain fibers regenerate, while
maintaining normal sensation, such as touch, pressure and position, and
without the risks of toxicities of NSAIDs and injected corticosteroids,
or the side effects, including abuse and addiction, associated with
opioid treatments. In January 2018, CNTX-4975 was granted Fast Track
designation by the U.S. Food and Drug Administration for the treatment
of pain associated with knee osteoarthritis.

About Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of
chronic moderate to severe pain with one of the largest, exclusively
pain-focused pipelines of non-opioid, non-addictive therapies in active
development. Centrexion Therapeutics recognizes the needs of over a
quarter of a billion people living with chronic pain worldwide, and aims
to develop new, safer and more effective therapies that overcome the
limitations and challenges associated with current pain treatments.
Founded by world-renowned leaders in drug development and well-funded by
key investors, Centrexion Therapeutics is building a pain treatment
powerhouse to address the substantial and growing global chronic pain
epidemic. For more information about Centrexion Therapeutics, visit

1. Deshpande, B., et al. Number of Persons With Symptomatic Knee
Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and
Obesity. Arthritis Care & Research. Published online November 3, 2016

View Comments and Join the Discussion!